The Board of Directors of Dabur India (DIL) met to consider the company’s unaudited financial results for the quarter ended 31 December 2020.
Dabur India continued to move forward on the growth track, riding on sustained efforts in driving demand for its Ayurvedic healthcare and personal care products. The benefits from its distribution footprint enhancement initiatives, coupled with strong innovation to meet the emerging consumer needs, helped Dabur end the third quarter of 2020-21 with its highest-ever quarterly Revenue and Profits. Consolidated Revenue for the quarter marked a 16% jump to Rs 2,729 crore, up from Rs 2,353 crore a year earlier. Consolidated net profit for the third quarter surged 23.7% at Rs 492 crore as against Rs 398 crore a year ago.
Dabur’s India FMCG business led the growth with a 19.5% surge, with an underlying FMCG volume growth of 18.1% during the Third Quarter of 2020-21. Dabur’s Standalone Revenue rose 18.5% to Rs 2,071 crore, while standalone net profit marked a 21.1% growth to Rs 400 crore.
“With the Covid fears receding and mobility improving, we have reported a stellar performance during the quarter with strong revenue and profit growth. Riding on our strategic business transformation exercise aimed at developing aggressive growth engines in the core business areas, our domestic healthcare vertical ended the quarter with a 28% growth. We are also witnessing a revival in discretionary spending by consumers, which helped the home and personal care business grow by 16%. Our international business has also staged a smart recovery and reported a growth of 13.5% during the quarter,” Dabur India chief executive officer Mohit Malhotra said.
“While competitive intensity remained high, we have successfully tapped the growth opportunities to deliver a strong performance during the quarter. Our focus on strengthening our core healthcare portfolio with heavy investments behind our power brands, coupled with investment in expanding our rural footprint and enhancing our go-to-market approach, continues to serve us well. This has enabled us to grow ahead of categories and gain market share across our portfolio,” Malhotra added.
The healthcare business continued to be the outperformer, growing by over 28% in Q3 of 2020-21. Within healthcare, the Health Supplements business reported a nearly 35% growth while the OTC business grew by 34%, and the Ayurvedic ethicals business reporting a 23% growth during the quarter.
The shampoos category reported a 27% growth, while the oral care business grew by 28% and hair oils by around 12%. Dabur’s foods business too marked a turnaround during the quarter with a 5% growth. Excluding the Institutional and HORECA business, which continues to be under pressure, Dabur’s foods business ended the quarter with a 16% growth.
International business staged a smart recovery and reported a growth of 13.5% in INR terms and 14.1% in Constant Currency terms. The Turkey business grew by 33%, while the SAARC business was up 16%. The MENA business posted a growth of 11.6%, while Egypt grew by 9.5%, and the Namaste business in US reported a 9% growth.
Dabur India is one of India’s leading FMCG Companies. Building on a legacy of quality and experience for 135 years, Dabur is said to be one of the world’s largest Ayurvedic and natural health care company. Dabur India’s FMCG portfolio today includes eight distinct power brands – Dabur Chyawanprash, Dabur Honey, Dabur Honitus, Dabur PudinHara, and Dabur Lal Tail in the healthcare space; Dabur Amla and Dabur Red Paste in the personal care category; and Réal in the foods category.